La Jolla Pharmaceutical (LJPC) 10-Q 5 Aug 21 2021 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2021	Jul. 23, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	1-36282
Entity Registrant Name	LA JOLLA PHARMACEUTICAL COMPANY
Entity Incorporation, State or Country Code	CA
Entity Tax Identification Number	33-0361285
Entity Address, Address Line One	201 Jones Road
Entity Address, Address Line Two	Suite 400
Entity Address, City or Town	Waltham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02451
City Area Code	617
Local Phone Number	715-3600
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	LJPC
Security Exchange Name	NASDAQ
Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Shell Company	false
Entity Common Stock, Shares Outstanding		27,488,137
Entity Central Index Key	0000920465
Document Period End Date	Jun. 30, 2021
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--12-31

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 45,888	$ 21,221
Accounts receivable, net	8,596	5,834
Inventory, net	5,481	6,013
Prepaid expenses and other current assets	5,201	3,388
Total current assets	65,166	36,456
Goodwill	20,123	20,123
Intangible assets, net	14,097	14,873
Right-of-use lease assets	419	536
Property and equipment, net	163	215
Restricted cash	40	40
Total assets	100,008	72,243
Current liabilities:
Accounts payable	1,846	2,762
Accrued expenses	12,175	6,494
Accrued payroll and related expenses	1,912	2,878
Lease liabilities, current portion	168	204
Total current liabilities	16,101	12,338
Deferred royalty obligation, net	124,470	124,437
Accrued interest expense on deferred royalty obligation, less current portion	22,136	19,111
Lease liabilities, less current portion	251	332
Other noncurrent liabilities	4,493	4,112
Total liabilities	167,451	160,330
Commitments and contingencies (Note 6)
Shareholders’ deficit:
Common Stock, $0.0001 par value; 100,000,000 shares authorized, 27,482,231 and 27,402,648 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively	3	3
Additional paid-in capital	987,249	984,756
Accumulated deficit	(1,058,601)	(1,076,752)
Total shareholders’ deficit	(67,443)	(88,087)
Total liabilities and shareholders’ deficit	100,008	72,243
Series C-1 Convertible Preferred Stock
Shareholders’ deficit:
Series C-12 Convertible Preferred Stock, $0.0001 par value; 11,000 shares authorized, 3,906 shares issued and outstanding at June 30, 2021 and December 31, 2020; and liquidation preference of $3,906 at June 30, 2021 and December 31, 2020	$ 3,906	$ 3,906

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Common stock, par value (USD per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	27,482,231	27,402,648
Common stock, shares outstanding (in shares)	27,482,231	27,402,648
Series C-1 Convertible Preferred Stock
Preferred stock, par value (USD per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	11,000	11,000
Preferred stock, shares issued (in shares)	3,906	3,906
Preferred stock, shares outstanding (in shares)	3,906	3,906
Preferred stock, liquidation	$ 3,906	$ 3,906

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenue
Total revenue	$ 16,059,000	$ 5,805,000	$ 50,196,000	$ 13,396,000
Operating expenses
Selling, general and administrative	8,996,000	8,677,000	17,751,000	16,829,000
Research and development	1,114,000	8,781,000	2,672,000	17,964,000
Total operating expenses	12,266,000	18,266,000	28,910,000	36,317,000
Income (loss) from operations	3,793,000	(12,461,000)	21,286,000	(22,921,000)
Other (expense) income
Interest expense	(2,672,000)	(2,470,000)	(5,281,000)	(4,876,000)
Interest income		32,000	2,000	222,000
Other income—related party	2,532,000	0	2,532,000	4,085,000
Other income (expense)	80,000	(693,000)	(370,000)	(693,000)
Total other (expense) income, net	(60,000)	(3,131,000)	(3,117,000)	(1,262,000)
Income (loss) before income taxes	3,733,000	(15,592,000)	18,169,000	(24,183,000)
Provision for income taxes	0	0	18,000	0
Net income (loss)	$ 3,733,000	$ (15,592,000)	$ 18,151,000	$ (24,183,000)
Earnings (loss) per share
Basic	$ 0.14	$ (0.57)	$ 0.66	$ (0.89)
Diluted	$ 0.11	$ (0.57)	$ 0.53	$ (0.89)
Shares used in computing earnings (loss) per share
Basic	27,461	27,326	27,444	27,282
Diluted	34,201	27,326	34,192	27,282
Product Sales
Revenue
Revenue	$ 11,059,000	$ 5,805,000	$ 19,696,000	$ 13,396,000
Operating expenses
Cost of product sales, license revenue	2,156,000	$ 808,000	4,887,000	$ 1,524,000
License Revenue
Revenue
Revenue	$ 5,000,000		30,500,000
Operating expenses
Cost of product sales, license revenue			$ 3,600,000

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Shareholders' Deficit (Unaudited) - USD ($) $ in Thousands	Total	Preferred StockSeries C-1 Convertible Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Beginning Balance at Dec. 31, 2019	$ (55,990)	$ 3,906	$ 3	$ 977,432	$ (1,037,331)
Beginning Balance (in shares) at Dec. 31, 2019		4	27,195
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	2,407			2,407
Issuance of common stock under 2013 Equity Plan	305			305
Issuance of common stock under 2013 Equity Plan (in shares)			44
Issuance of common stock under ESPP	200			200
Issuance of common stock under ESPP (in shares)			38
Net income (loss)	(8,591)				(8,591)
Ending Balance at Mar. 31, 2020	(61,669)	$ 3,906	$ 3	980,344	(1,045,922)
Ending Balance (in shares) at Mar. 31, 2020		4	27,277
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	2,407			2,407
Issuance of common stock under 2013 Equity Plan	305			305
Issuance of common stock under ESPP	200			200
Issuance of common stock under ESPP (in shares)			38
Net income (loss)	(8,591)				(8,591)
Ending Balance at Mar. 31, 2020	(61,669)	$ 3,906	$ 3	980,344	(1,045,922)
Ending Balance (in shares) at Mar. 31, 2020		4	27,277
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under 2013 Equity Plan (in shares)			44
Beginning Balance at Dec. 31, 2019	(55,990)	$ 3,906	$ 3	977,432	(1,037,331)
Beginning Balance (in shares) at Dec. 31, 2019		4	27,195
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(24,183)
Ending Balance at Jun. 30, 2020	(75,212)	$ 3,906	$ 3	982,393	(1,061,514)
Ending Balance (in shares) at Jun. 30, 2020		4	27,359
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(24,183)
Ending Balance at Jun. 30, 2020	(75,212)	$ 3,906	$ 3	982,393	(1,061,514)
Ending Balance (in shares) at Jun. 30, 2020		4	27,359
Beginning Balance at Mar. 31, 2020	(61,669)	$ 3,906	$ 3	980,344	(1,045,922)
Beginning Balance (in shares) at Mar. 31, 2020		4	27,277
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	1,590			1,590
Issuance of common stock under 2013 Equity Plan	300			300
Issuance of common stock under 2013 Equity Plan (in shares)			50
Issuance of common stock under ESPP	159			159
Issuance of common stock under ESPP (in shares)			32
Net income (loss)	(15,592)				(15,592)
Ending Balance at Jun. 30, 2020	(75,212)	$ 3,906	$ 3	982,393	(1,061,514)
Ending Balance (in shares) at Jun. 30, 2020		4	27,359
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	1,590			1,590
Issuance of common stock under 2013 Equity Plan	300			300
Issuance of common stock under ESPP	159			159
Issuance of common stock under ESPP (in shares)			32
Net income (loss)	(15,592)				(15,592)
Ending Balance at Jun. 30, 2020	(75,212)	$ 3,906	$ 3	982,393	(1,061,514)
Ending Balance (in shares) at Jun. 30, 2020		4	27,359
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under 2013 Equity Plan (in shares)			50
Beginning Balance at Dec. 31, 2020	(88,087)	$ 3,906	$ 3	984,756	(1,076,752)
Beginning Balance (in shares) at Dec. 31, 2020		4	27,403
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	1,116			1,116
Issuance of common stock under 2013 Equity Plan	154			154
Issuance of common stock under 2013 Equity Plan (in shares)			29
Issuance of common stock under ESPP	81			81
Issuance of common stock under ESPP (in shares)			17
Net income (loss)	14,418				14,418
Ending Balance at Mar. 31, 2021	(72,318)	$ 3,906	$ 3	986,107	(1,062,334)
Ending Balance (in shares) at Mar. 31, 2021		4	27,449
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	1,116			1,116
Issuance of common stock under 2013 Equity Plan	154			154
Issuance of common stock under ESPP	81			81
Issuance of common stock under ESPP (in shares)			17
Net income (loss)	14,418				14,418
Ending Balance at Mar. 31, 2021	(72,318)	$ 3,906	$ 3	986,107	(1,062,334)
Ending Balance (in shares) at Mar. 31, 2021		4	27,449
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under 2013 Equity Plan (in shares)			29
Beginning Balance at Dec. 31, 2020	$ (88,087)	$ 3,906	$ 3	984,756	(1,076,752)
Beginning Balance (in shares) at Dec. 31, 2020		4	27,403
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under 2013 Equity Plan (in shares)	29,379
Net income (loss)	$ 18,151
Ending Balance at Jun. 30, 2021	(67,443)	$ 3,906	$ 3	987,249	(1,058,601)
Ending Balance (in shares) at Jun. 30, 2021		4	27,482
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	18,151
Ending Balance at Jun. 30, 2021	$ (67,443)	$ 3,906	$ 3	987,249	(1,058,601)
Ending Balance (in shares) at Jun. 30, 2021		4	27,482
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under 2013 Equity Plan (in shares)	29,379
Beginning Balance at Mar. 31, 2021	$ (72,318)	$ 3,906	$ 3	986,107	(1,062,334)
Beginning Balance (in shares) at Mar. 31, 2021		4	27,449
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	1,024			1,024
Issuance of common stock under 2013 Equity Plan	1			1
Issuance of common stock under ESPP	117			117
Issuance of common stock under ESPP (in shares)			33
Net income (loss)	3,733				3,733
Ending Balance at Jun. 30, 2021	(67,443)	$ 3,906	$ 3	987,249	(1,058,601)
Ending Balance (in shares) at Jun. 30, 2021		4	27,482
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	1,024			1,024
Issuance of common stock under 2013 Equity Plan	1			1
Issuance of common stock under ESPP	117			117
Issuance of common stock under ESPP (in shares)			33
Net income (loss)	3,733				3,733
Ending Balance at Jun. 30, 2021	$ (67,443)	$ 3,906	$ 3	$ 987,249	$ (1,058,601)
Ending Balance (in shares) at Jun. 30, 2021		4	27,482

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited)	3 Months Ended	6 Months Ended
	Jun. 30, 2021USD ($)	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)
Operating activities
Net income (loss)	$ 3,733,000	$ 18,151,000	$ (24,183,000)
Adjustments to reconcile net income (loss) to net cash provided by (used for) operating activities:
Share-based compensation expense		2,140,000	3,997,000
Depreciation expense		56,000	1,798,000
Non-cash interest expense		3,718,000	3,392,000
Inventory fair value step-up adjustment included in cost of product sales		850,000
Amortization of intangible assets	400,000	776,000	0
Loss on change in fair value of contingent value rights		370,000
Amortization of right-of-use lease assets		117,000	699,000
Loss on disposal of property and equipment			904,000
Unrealized gains on short-term investments			(63,000)
Changes in operating assets and liabilities:
Accounts receivable, net		(2,762,000)	1,117,000
Inventory, net		(318,000)	(909,000)
Prepaid expenses and other current assets		(1,813,000)	1,675,000
Accounts payable		(920,000)	(1,696,000)
Accrued expenses		5,032,000	(3,378,000)
Accrued payroll and related expenses		(966,000)	(2,591,000)
Lease liabilities		(117,000)	(1,357,000)
Net cash provided by (used for) operating activities		24,314,000	(20,595,000)
Investing activities
Proceeds from the sale of property and equipment			2,860,000
Purchases of short-term investments			(2,999,000)
Net cash used for investing activities			(139,000)
Financing activities
Net proceeds from issuance of common stock under 2013 Equity Plan		155,000	605,000
Net proceeds from issuance of common stock under ESPP		198,000	359,000
Net cash provided by financing activities		353,000	964,000
Net increase (decrease) in cash, cash equivalents and restricted cash		24,667,000	(19,770,000)
Cash, cash equivalents and restricted cash, beginning of period		21,261,000	88,729,000
Cash, cash equivalents and restricted cash, end of period	45,928,000	45,928,000	68,959,000
Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets
Cash and cash equivalents	45,888,000	45,888,000	68,353,000
Restricted cash	40,000	40,000	606,000
Cash, cash equivalents and restricted cash, end of period	$ 45,928,000	$ 45,928,000	$ 68,959,000

Business

Business	6 Months Ended
	Jun. 30, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Business	1. Business La Jolla Pharmaceutical Company (collectively with its wholly owned subsidiaries, “La Jolla” or the “Company”) is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. GIAPREZA ™ ™ On July 28, 2020, La Jolla completed its acquisition of Tetraphase Pharmaceuticals, Inc. and its subsidiaries (“Tetraphase”), a biopharmaceutical company focused on commercializing XERAVA, for $43 million in upfront cash plus potential future cash payments of up to $16 million. The Company’s consolidated financial results exclude Tetraphase’s financial results prior to the acquisition closing date of July 28, 2020 (see Note 11). In January 2021, La Jolla and certain of its wholly owned subsidiaries, including La Jolla Pharma, LLC, entered into a license agreement with PAION AG to commercialize GIAPREZA and XERAVA in the European Economic Area, the United Kingdom and Switzerland. Pursuant to the agreement: (i) the Company has received an upfront cash payment of $22.5 million, less a 15% refundable withholding tax; and (ii) the Company is entitled to receive potential commercial milestone payments of up to $109.5 million and royalties on net sales of GIAPREZA and XERAVA. As of June 30, 2021 and December 31, 2020, the Company had cash and cash equivalents of $45.9 million and $21.2 million, respectively. Based on the Company’s current operating plans and projections, the Company expects that its existing cash and cash equivalents will be sufficient to fund operations for at least one year from the date this Quarterly Report on Form 10-Q is filed with the U.S. Securities and Exchange Commission (the “SEC”). The Company expects to fund future operations with existing cash or cash generated from operations.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	2. Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation and Use of Estimates The Company’s condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of SEC Regulation S-X. Accordingly, certain information and disclosures required by GAAP for annual financial statements have been omitted. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2020 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 8, 2021 (the “Form 10-K”). The accompanying condensed consolidated financial statements include the accounts of La Jolla Pharmaceutical Company and its wholly owned subsidiaries. All inter-company transactions and balances have been eliminated in consolidation. The preparation of the Company’s condensed consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in the Company’s condensed consolidated financial statements and the accompanying notes. Actual results may differ materially from these estimates. Certain amounts previously reported in the financial statements have been reclassified to conform to the current year presentation. Such reclassifications did not affect net loss, shareholders’ deficit or cash flows. The results of operations for the three and six months ended June 30, 2021 are not necessarily indicative of the results to be expected for the full year or any future interim periods. The accompanying condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited consolidated balance sheet as of December 31, 2020 contained in the Form 10-K. Summary of Significant Accounting Policies During the six months ended June 30, 2021, other than the license revenue recognition policy described below, there have been no changes to the Company’s significant accounting policies as described in Note 2 of the Form 10-K. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist of cash. The Company maintains its cash in checking and savings accounts at federally insured financial institutions in excess of federally insured limits. During the six months ended June 30, 2021, 399 hospitals in the U.S. purchased GIAPREZA. During the six months ended June 30, 2021, 644 hospitals and other healthcare organizations in the U.S. purchased XERAVA. Hospitals and other healthcare organizations U.S. Net Product Sales Accounts Receivable Three Months Ended June 30, 2021 Six Months Ended June 30, 2021 As of June 30, 2021 Customer A 34 % 36 % 37 % Customer B 35 % 34 % 48 % Customer C 27 % 26 % 12 % Total 96 % 96 % 97 % Business Combinations The Company accounts for business combinations using the acquisition method pursuant to the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) Intangible Assets Intangible assets acquired in a business combination are initially recorded at fair value. Intangible assets with a definite useful life are amortized on a straight-line basis over the estimated useful life of the related assets. Intangible assets with an indefinite useful life are not amortized. The Company reviews its intangible assets for impairment at least annually or whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If such circumstances are determined to exist, an estimate of undiscounted future cash flows produced by the asset, including its eventual residual value, is compared to the carrying value to determine whether impairment exists. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Fair value is estimated through discounted cash flow models to project cash flows from the asset. The Company recognized no impairment charge for the six months ended June 30 , 2021 . Goodwill Goodwill represents the excess of the Purchase Price over the fair value of the net assets acquired as of the acquisition date. Goodwill has an indefinite useful life and is not amortized. The Company reviews its goodwill for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of the Company may exceed its fair value. The Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of the Company is less than its carrying amount, including goodwill. If that is the case, the Company performs a quantitative impairment test, and, if the carrying amount of the Company exceeds its fair value, then the Company will recognize an impairment charge for the amount by which its carrying amount exceeds its fair value, not to exceed the carrying amount of the goodwill. The Company recognized no impairment charge for the six months ended June 30, 2021. Revenue Recognition Pursuant to FASB ASC Topic 606 Product Sales Revenue from product sales is recorded at the transaction price, net of estimates for variable consideration consisting of chargebacks, discounts, returns, Medicaid rebates and administrative fees. Variable consideration is estimated using the expected-value amount method, which is the sum of probability-weighted amounts in a range of possible consideration amounts. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results vary materially from the Company’s estimates, the Company will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted. These items include: • Chargebacks—Chargebacks are discounts the Company provides to distributors in the event that the sales prices to end users are below the distributors’ acquisition price. This may occur due to a direct contract with a health system, a group purchasing organization (“GPO”) agreement or a sale to a government facility. Chargebacks are estimated based on known chargeback rates and recorded as a reduction of revenue on delivery to the Company’s customers. • Discounts—The Company offers customers various forms of incentives and consideration, including prompt-pay and other discounts. The Company estimates discounts primarily based on contractual terms. These discounts are recorded as a reduction of revenue on delivery to the Company’s customers. • Returns—The Company offers customers a limited right of return, generally for damaged or expired product. The Company estimates returns based on an internal analysis, which includes actual experience. The estimates for returns are recorded as a reduction of revenue on delivery to the Company’s customers. • Medicaid Rebates—We participate in Medicaid rebate programs, which provide assistance to certain low-income patients based on each individual state’s guidelines regarding eligibility and services. Under the Medicaid rebate programs, we pay a rebate to each participating state, generally within three months after the quarter in which product was sold. The estimates for rebates are recorded as a reduction of revenue on delivery to the Company’s customers . • Administrative Fees—The Company pays administrative fees to GPOs for services and access to data. Additionally, the Company pays an Industrial Funding Fee as part of the U.S. General Services Administration’s Federal Supply Schedules program. These fees are based on contracted terms and are paid after the quarter in which the product was purchased by the applicable GPO or government agency. Administrative fees are recorded as a reduction of revenue on delivery to customers. The Company will continue to assess its estimates of variable consideration as it accumulates additional historical data and will adjust these estimates accordingly. License Revenue We enter into out-license agreements with counterparties to develop and/or commercialize our products in territories outside of the U.S. in exchange for: (i) nonrefundable, upfront license fees; (ii) development and regulatory milestone payments; and/or (iii) sales-based royalties and milestones. If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from nonrefundable, upfront fees allocated to the license when the license is transferred to the customer and the customer can benefit from the license. For licenses that are bundled with other performance obligations, management uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable, upfront fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of progress and related revenue recognition. At the inception of each arrangement that include milestone and other payments, other than sales-based milestone payments and nonrefundable, upfront license fees, we evaluate whether achieving each milestone payment or other payment is considered probable and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestone payments that are not within our control, such as approvals from regulators or where attainment of the specified event is dependent on the development activities of a third party, are not considered probable of being achieved until those approvals are received or the specified event occurs. For arrangements that include sales-based royalties and milestone payments, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of: (i) when the related sales occur; or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. We enter into commercial supply agreements with our out-licensees to supply our products in territories outside the U.S. in exchange for: (i) nonrefundable, upfront fees; and/or (ii) the reimbursement of manufacturing costs, plus a margin in certain cases. The Company is considered the principal in these arrangements for accounting purposes as it controls the promised goods before transferring these goods to the out-licensee. The Company recognizes revenue when out-licensees obtain control of the Company’s product, which typically occurs on delivery. Recent Accounting Pronouncements The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position and results of operations.

Earnings (Loss) per Share

Earnings (Loss) per Share	6 Months Ended
	Jun. 30, 2021
Earnings Per Share [Abstract]
Earnings (Loss) per Share	3. Earnings (Loss) per Share Basic earnings (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding during the period, without consideration of potential common shares. Diluted earnings (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding plus potential common shares. Convertible preferred stock and stock options are considered potential common shares and are included in the calculation of diluted earnings (loss) per share using the treasury stock method when their effect is dilutive. Potential common shares are excluded from the calculation of diluted earnings (loss) per share when their effect is anti-dilutive. For the three months ended June 30, 2021, there were 6.7 million potential common shares that were included in the calculation of diluted earnings per share, which consists of: (i) 6.7 million shares of common stock issuable upon conversion of existing convertible preferred stock; and (ii) 5,000 stock options. For the six months ended June 30, 2021, there were 6.7 million potential common shares that were included in the calculation of diluted earnings per share, which consists of: (i) 6.7 million shares of common stock issuable upon conversion of existing convertible preferred stock; and (ii) 13,000 stock options. For the three and six months ended June 30, 2021 and 2020, there were 4.1 million and 10.2 million, respectively, of potential common shares that were excluded from the calculation of diluted loss per share because their effect was anti-dilutive.

Balance Sheet Details

Balance Sheet Details	6 Months Ended
	Jun. 30, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Balance Sheet Account Details	4. Balance Sheet Details Restricted Cash Restricted cash as of June 30, 2021 and December 31, 2020 consisted of a $40,000 security deposit for the Company’s corporate purchasing credit card. Inventory, Net Inventory, net consisted of the following (in thousands): June 30, December 31, 2021 2020 Raw materials $ 802 $ 802 Work-in-process 3,636 3,213 Finished goods 1,043 1,998 Total inventory, net $ 5,481 $ 6,013 As of June 30, 2021 and December 31, 2020, inventory, net included zero and $0.9 million, respectively, of the fair value step-up adjustment to Tetraphase’s inventory recorded in connection with the acquisition of Tetraphase (see Note 11). As of June 30, 2021 and December 31, 2020, total inventory is recorded net of inventory reserves of $1.2 million and $0.9 million, respectively. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following (in thousands): June 30, December 31, 2021 2020 Refundable withholding tax $ 3,375 $ - Prepaid manufacturing costs 491 930 Prepaid clinical costs 265 820 Prepaid insurance 263 505 Other prepaid expenses and current assets 807 1,133 Total prepaid expenses and other current assets $ 5,201 $ 3,388 Property and Equipment, Net Property and equipment, net consisted of the following (in thousands): June 30, December 31, 2021 2020 Furniture and fixtures $ 313 $ 309 Computer hardware 310 310 Software 203 733 Total property and equipment, gross 826 1,352 Accumulated depreciation and amortization (663 ) (1,137 ) Total property and equipment, net $ 163 $ 215 Intangible Assets, Net Intangible assets, net consisted of the following (in thousands): Useful Life June 30, December 31, (years) 2021 2020 Technology 10 $ 14,000 $ 14,000 Trade name 10 1,520 1,520 Total intangible assets, gross 15,520 15,520 Accumulated amortization (1,423 ) (647 ) Total intangible assets, net $ 14,097 $ 14,873 The intangible assets were recorded in connection with the acquisition of Tetraphase (see Note 11). Accrued Expenses Accrued expenses consisted of the following (in thousands): June 30, December 31, 2021 2020 Accrued interest expense on deferred royalty obligation, current portion $ 4,227 $ 3,567 Deferred revenue 3,037 188 Accrued royalties and in-license fees 1,235 685 Accrued manufacturing costs 1,469 627 Accrued professional fees 942 660 Accrued other 1,265 767 Total accrued expenses $ 12,175 $ 6,494 Other Noncurrent Liabilities Other noncurrent liabilities consisted of the following (in thousands): June 30, December 31, 2021 2020 Paycheck Protection Program loan $ 2,313 $ 2,302 Fair value of contingent value rights (see Note 11) 2,180 1,810 Total other noncurrent liabilities $ 4,493 $ 4,112 On April 22, 2020, Tetraphase entered into a promissory note for $2.3 million under the Paycheck Protection Program (the “PPP Loan”). The interest rate on the PPP Loan is 1.0% per annum. The PPP Loan is unsecured and guaranteed by the U.S. Small Business Administration. The principal amount of the PPP Loan may be forgiven under the Paycheck Protection Program, subject to certain requirements and to the extent that the PPP Loan proceeds are used to pay permitted expenses, including certain payroll, rent and utility payments. The Company applied for forgiveness of the PPP Loan. The Company will be obligated to make monthly payments of principal and interest with respect to any unforgiven portion of the PPP Loan. The obligation to repay the PPP Loan may be accelerated upon the occurrence of an event of default.

Deferred Royalty Obligation

Deferred Royalty Obligation	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
Deferred Royalty Obligation	5. Deferred Royalty Obligation In May 2018, the Company closed a $125.0 million royalty financing agreement (the “Royalty Agreement”) with HealthCare Royalty Partners (“HCR”). Under the terms of the Royalty Agreement, the Company received $125.0 million in exchange for tiered royalty payments on worldwide net sales of GIAPREZA. HCR is entitled to receive quarterly royalties on worldwide net sales of GIAPREZA beginning April 1, 2018. Quarterly payments to HCR under the Royalty Agreement start at a maximum royalty rate, with step-downs based on the achievement of annual net product sales thresholds. Through December 31, 2021, the royalty rate will be a maximum of 10%. Starting January 1, 2022, the maximum royalty rate may increase by 4% if an agreed-upon, cumulative net product sales threshold has not been met, and, starting January 1, 2024, the maximum royalty rate may increase by an additional 4% if a different agreed-upon, cumulative net product sales threshold has not been met. The Royalty Agreement is subject to maximum aggregate royalty payments to HCR of $225.0 million. The Royalty Agreement expires upon the first to occur of January 1, 2031 or when the maximum aggregate royalty payments have been made. The Royalty Agreement was entered into by the Company’s wholly owned subsidiary, La Jolla Pharma, LLC, and HCR has no recourse under the Royalty Agreement against La Jolla Pharmaceutical Company or any assets other than GIAPREZA. On receipt of the $125.0 million payment from HCR, the Company recorded a deferred royalty obligation of $125.0 million, net of issuance costs of $0.7 million. For the three and six months ended June 30, 2021, the Company recognized interest expense, including amortization of the obligation discount, of $2.7 million and $5.3 million, respectively. For the three and six months ended June 30, 2020, the Company recognized interest expense, including amortization of the obligation discount, of $2.5 million and $4.9 million, respectively. The carrying value of the deferred royalty obligation as of June 30, 2021 and December 31, 2020 was $124.5 million and $124.4 million, respectively, net of unamortized obligation discount of $0.5 million and $0.6 million, respectively, and was classified as a noncurrent liability. The related accrued interest expense as of June 30, 2021 and December 31, 2020 was $26.4 million and $22.7 million, respectively, of which $22.1 million and $19.1 million was classified as noncurrent liabilities, respectively. During the three and six months ended June 30, 2021, the Company made royalty payments to HCR of $0.7 million and $1.6 million, respectively. As of June 30, 2021 and December 31, 2020, the Company recorded royalty obligations payable of $0.9 million and $0.9 million, respectively, in accrued expenses. The deferred royalty obligation is classified as Level 3 in the FASB ASC Topic 820-10, three-tier fair value hierarchy, and its carrying value approximates fair value. Under the terms of the Royalty Agreement, La Jolla Pharma, LLC has certain obligations, including the obligation to use commercially reasonable and diligent efforts to commercialize GIAPREZA. If La Jolla Pharma, LLC is held to not have met these obligations, HCR would have the right to terminate the Royalty Agreement and demand payment from La Jolla Pharma, LLC of either $125.0 million or $225.0 million (depending on which obligation La Jolla Pharma, LLC is held to not have met), minus aggregate royalties already paid to HCR. In the event that La Jolla Pharma, LLC fails to timely pay such amount if and when due, HCR would have the right to foreclose on the GIAPREZA-related assets. The Company concluded that certain of these contract provisions that could result in an acceleration of amounts due under the Royalty Agreement are embedded derivatives that require bifurcation from the deferred royalty obligation and fair value recognition. The Company determined the fair value of each derivative by assessing the probability of each event occurring, as well as the potential repayment amounts and timing of such repayments that would result under various scenarios. As a result of this assessment, the Company determined that the fair value of the embedded derivatives is immaterial as of June 30, 2021 and December 31, 2020. Each reporting period, the Company estimates the fair value of the embedded derivatives until the features lapse and/or the termination of the Royalty Agreement. Any material change in the fair value of the embedded derivatives will be recorded as either a gain or loss on the consolidated statements of operations.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2021
Leases [Abstract]
Commitments and Contingencies	6. Commitments and Contingencies Lease Commitments Future minimum lease payments, excluding Lease Operating Costs, as of June 30, 2021 are as follows (in thousands): 2021 $ 108 2022 181 2023 166 Thereafter - Total future minimum lease payments 455 Less: discount 36 Total lease liabilities $ 419 Lease expense under current leases was approximately $0.1 million and $0.2 million for the three and six months ended June 30, 2021, respectively. Lease expense under former leases was approximately $0.7 million and $1.4 million for the three and six months ended June 30, 2020, respectively. Cash paid for amounts included in the measurement of lease liabilities was $51,000 and $0.1 million for the three and six months ended June 30, 2021, respectively. Cash paid for amounts included in the measurement of lease liabilities was $1.0 and $1.9 million for the three and six months ended June 30, 2020, respectively. As of June 30, 2021, the weighted-average remaining lease term and the weighted-average discount rate for the Company’s only operating lease, the Waltham Sublease, was 2.3 years and 3.5%, respectively. Waltham Sublease In December 2020, the Company entered into a sublease agreement for office space in Waltham, Massachusetts (the “Waltham Sublease”). The Waltham Sublease commenced on December 21, 2020 and expires on November 30, 2023. In addition to rent of approximately $15,000 per month, the Waltham Sublease requires the Company to pay certain taxes, insurance and operating costs relating to the leased premises (collectively, “Lease Operating Costs”). The Waltham Sublease contains customary default provisions, representations, warranties and covenants. The Waltham Sublease is classified as an operating lease. The Company recognizes the Waltham Sublease expense in the consolidated statements of operations and records a lease liability and right-of-use asset for this lease. San Diego Sublease In September 2020, the Company entered into a sublease agreement for office space in San Diego, California with an entity of which the Chairman of the Company’s board of directors is also the chairman and chief executive officer (the “San Diego Sublease”). The San Diego Sublease term is approximately 7 years, and the rent is approximately $12,000 per month. The San Diego Sublease is cancellable without penalty by either party with 30-days’ written notice. The San Diego Sublease is a short-term lease for accounting purposes. The Company made payments of approximately $28,000 and $67,000 under the San Diego Sublease during the three and six months ended June 30, 2021. The Company recognizes the San Diego Sublease payments in the consolidated statements of operations and does not record a lease liability or right-of-use asset for this lease. Contingencies From time to time, the Company may become subject to claims and litigation arising in the ordinary course of business. The Company is not a party to any material legal proceedings, nor is it aware of any material pending or threatened litigation.

Shareholders Equity

Shareholders Equity	6 Months Ended
	Jun. 30, 2021
Equity [Abstract]
Shareholders Equity	7. Shareholders’ Equity Preferred Stock As of June 30, 2021 and December 31, 2020, 3,906 shares of Series C-1 2 2 2 2 2

Equity Incentive Plans

Equity Incentive Plans	6 Months Ended
	Jun. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Equity Incentive Plans	8. Equity Incentive Plans 2013 Equity Incentive Plan A total of 9,600,000 shares of common stock have been reserved for issuance under the La Jolla Pharmaceutical Company 2013 Equity Incentive Plan (the “2013 Equity Plan”). As of June 30, 2021 and December 31, 2020, 5,514,933 shares of common stock and 5,478,334 shares of common stock, respectively, remained available for future grants under the 2013 Equity Plan. 2018 Employee Stock Purchase Plan A total of 750,000 shares of common stock have been reserved for issuance under the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan (the “ESPP”). As of June 30, 2021 and December 31, 2020, 405,564 shares of common stock and 455,768 shares of common stock, respectively, remained available for future grants under the ESPP. Equity Awards The activity related to equity awards, which are comprised of stock options, during the six months ended June 30, 2021 is summarized as follows: Equity Awards Weighted- average Exercise Price per Share Weighted- average Remaining Contractual Term ( 1) (years) Aggregate Intrinsic Value ( 2) (millions) Outstanding at December 31, 2020 4,121,666 $ 8.67 Granted 562,329 $ 4.96 Exercised (29,379 ) $ 5.23 Cancelled/forfeited (569,549 ) $ 9.21 Outstanding at June 30, 2021 4,085,067 $ 8.10 8.3 $ 0.2 Exercisable at June 30, 2021 1,107,878 $ 16.71 5.7 $ - (1) (2) Share-based Compensation Expense The classification of share-based compensation expense is summarized as follows (in thousands): Three Months Ended Six Months Ended June 30, June 30, 2021 2020 2021 2020 Selling, general and administrative $ 977 $ 626 $ 1,817 $ 1,470 Research and development 47 964 323 2,527 Total share-based compensation expense $ 1,024 $ 1,590 $ 2,140 $ 3,997 As of June 30, 2021, total unrecognized share-based compensation expense related to unvested equity awards was $8.9 million, which is expected to be recognized over a weighted-average period of 3.0 years. As of June 30, 2021, there was no unrecognized share-based compensation expense related to shares of common stock issued under the ESPP.

Other Income_Related Party

Other Income—Related Party	6 Months Ended
	Jun. 30, 2021
Related Party Transactions [Abstract]
Other Income—Related Party	9. Other Income—Related Party The Company has a non-voting profits interest in a related party, which provides the Company with the potential to receive a portion of the future distributions of profits, if any. Investment funds affiliated with the Chairman of the Company’s board of directors have a controlling interest in the related party. During the three and six months ended June 30, 2021, the Company received distributions of $2.5 million in connection with this profits interest. During the three and six months ended June 30, 2020, the Company received distributions of zero and $4.1 million, respectively, in connection with this profits interest.

License Agreements

License Agreements	6 Months Ended
	Jun. 30, 2021
Research And Development [Abstract]
License Agreements	10. License Agreements In-license Agreements George Washington University In December 2014, the Company entered into a patent license agreement with George Washington University (“GW”), which was subsequently amended and restated (the “GW License”) and assigned to La Jolla Pharma, LLC. Pursuant to the GW License, GW exclusively licensed to the Company certain intellectual property rights relating to GIAPREZA, including the exclusive rights to certain issued patents and patent applications covering GIAPREZA. Under the GW License, La Jolla Pharma, LLC is obligated to use commercially reasonable efforts to develop, commercialize, market and sell GIAPREZA. The Company has paid a one-time license initiation fee, annual maintenance fees, an amendment fee, additional payments following the achievement of certain development and regulatory milestones and royalties. As a result of the European Commission’s approval of GIAPREZA in August 2019, the Company made a milestone payment to GW in the amount of $0.5 million in the first quarter of 2020. The Company is obligated to pay a 6% royalty on net sales of GIAPREZA and 15% on payments received from sublicensees. The obligation to pay royalties under this agreement extends through the last-to-expire patent covering GIAPREZA. During the three and six months ended June 30, 2021, the Company made payments to GW of $0.4 million and $3.2 million, respectively. Harvard University In August 2006, the Company entered into a license agreement with Harvard University (“Harvard”), which was subsequently amended and restated (the “Harvard License”). Pursuant to the Harvard License, Harvard exclusively licensed to the Company certain intellectual property rights relating to tetracycline-based products, including XERAVA, including the exclusive rights to certain issued patents and patent applications covering such products. Under the Harvard License, the Company is obligated to use commercially reasonable efforts to develop, commercialize, market and sell tetracycline-based products, including XERAVA. For each product covered by the Harvard License, the Company is obligated to make certain payments for the following: (i) up to approximately upon the achievement of certain clinical development and regulatory milestones; (ii) a 5% royalty on direct U.S. net sales of XERAVA; (iii) a single-digit tiered royalty on direct ex-U.S. net sales of XERAVA, starting at a minimum royalty rate of 4.5%, with step-ups to a maximum royalty of 7.5% based on the achievement of annual net product sales thresholds; and (iv) 20% on payments received from sublicensees. The obligation to pay royalties under this agreement extends through the last-to-expire patent covering tetracycline-based products, including XERAVA. Paratek Pharmaceuticals, Inc. In March 2019, the Company entered into a license agreement with Paratek Pharmaceuticals, Inc. (“Paratek”), which was subsequently amended and restated (the “Paratek License”). Pursuant to the Paratek License, Paratek non-exclusively licensed to the Company certain intellectual property rights relating to XERAVA, including non-exclusive rights to certain issued patents and patent applications covering XERAVA. The Company is obligated to pay Paratek a 2.25% royalty based on direct U.S. net sales of XERAVA. The Company’s obligation to pay royalties with respect to the licensed product is retroactive to the date of the first commercial sale of XERAVA and shall continue until there are no longer any valid claims of the Paratek patents, which will expire in October 2023. Out-license Agreements PAION AG On January 12, 2021, La Jolla Pharmaceutical Company and certain of its wholly owned subsidiaries, including La Jolla Pharma, LLC, entered into an exclusive license agreement (the “PAION License”) with PAION AG and its wholly owned subsidiary (collectively, “PAION”). Pursuant to the PAION License, La Jolla granted PAION an exclusive license to commercialize GIAPREZA and XERAVA in the European Economic Area, the United Kingdom and Switzerland (collectively, the “PAION Territory”). La Jolla has received an upfront cash payment of $22.5 million, less a 15% refundable withholding tax, and is entitled to receive potential commercial milestone payments of up to $109.5 million and double-digit tiered royalty payments. In addition, royalties payable under the PAION License will be subject to reduction on account of generic competition and after patent expiration in a jurisdiction. Pursuant to the PAION License, PAION will be solely responsible for the future development and commercialization of GIAPREZA and XERAVA in the PAION Territory. PAION is required to use commercially reasonable efforts to commercialize GIAPREZA and XERAVA in the PAION Territory. The Company has not received any payments from PAION related to either royalties or commercial milestones. On July 13, 2021, the Company entered into a commercial supply agreement with PAION whereby the Company will supply PAION a minimum quantity of GIAPREZA and XERAVA through July 13, 2024. The supply agreement will automatically renew until the earlier of July 13, 2027, or until a new supply agreement is executed. During the initial 3-year term of the supply agreement, the Company will be reimbursed for direct and certain indirect manufacturing costs at cost. Everest Medicines Limited In February 2018, the Company entered into a license agreement with Everest, which was subsequently amended and restated (the “Everest License”). Pursuant to the Everest License, the Company granted Everest an exclusive license to develop and commercialize XERAVA for the treatment of cIAI and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, Singapore, the Malaysian Federation, the Kingdom of Thailand, the Republic of Indonesia, the Socialist Republic of Vietnam and the Republic of the Philippines (collectively, the “Everest Territory”). The Company is eligible to receive an additional $8.0 million regulatory milestone payment and up to an aggregate of $20.0 million in sales milestone payments. In May 2021, the Company entered into a commercial supply agreement with Everest whereby the Company will supply Everest a minimum quantity of XERAVA through December 31, 2023 and will transfer to Everest certain XERAVA-related manufacturing know-how. Pursuant to the supply agreement: (i) the Company has received $6.8 million of upfront payments comprised of: (1) a $4.0 million upfront technology transfer payment; and (2) a $2.8 million partial prepayment for XERAVA that is expected to be delivered to Everest during 2022; (ii) the Company will receive an additional $1.0 million technology transfer payment by January 30, 2022; and (iii) the Company will be reimbursed for direct and certain indirect manufacturing costs at 110% of costs through December 31, 2023. The Company recognized the $5.0 million of technology transfer-related payments as license revenue during the three and six months ended June 30, 2021 as Everest obtained control of the XERAVA-related manufacturing know-how prior to June 30, 2021. The Company recognized the $2.8 million partial prepayment for XERAVA that is expected to be delivered to Everest during 2022 as deferred revenue as of June 30, 2021 as the performance obligation to deliver XERAVA has not yet been satisfied.

Acquisition of Tetraphase Pharm

Acquisition of Tetraphase Pharmaceuticals, Inc	6 Months Ended
	Jun. 30, 2021
Business Combinations [Abstract]
Acquisition of Tetraphase Pharmaceuticals, Inc	11. Acquisition of Tetraphase Pharmaceuticals, Inc. On June 24, 2020, La Jolla entered into an Agreement and Plan of Merger with Tetraphase, a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA to treat serious and life‑threatening infections, and TTP Merger Sub, Inc., a wholly owned subsidiary of La Jolla. On July 28, 2020, La Jolla completed its acquisition of Tetraphase for $43 million in upfront cash plus potential future cash payments of up to $16 million pursuant to contingent value rights (“CVRs”). The holders of the CVRs are entitled to receive potential future cash payments of up to $16 million in the aggregate upon the achievement of certain net sales of XERAVA in the U.S. as follows: (i) $2.5 million if 2021 XERAVA U.S. net sales are at least $20 million; (ii) $4.5 million if XERAVA U.S. net sales are at least $35 million during any calendar year ending on or prior to December 31, 2024; and (iii) $9 million if XERAVA U.S. net sales are at least $55 million during any calendar year ending on or prior to December 31, 2024. Following the acquisition, Tetraphase became a wholly owned subsidiary of La Jolla. The acquisition of Tetraphase was accounted for as a business combination using the acquisition method pursuant to FASB ASC Topic 805. As the acquirer for accounting purposes, La Jolla has estimated the Purchase Price, assets acquired and liabilities assumed as of the acquisition date, with the excess of the Purchase Price over the fair value of net assets acquired recognized as goodwill. The estimated fair value of assets acquired and liabilities assumed in certain cases may be subject to revision based on the final determination of fair value. The Purchase Price is comprised of the upfront cash of $43 million and the estimated fair value of potential future cash payments pursuant to the CVRs. The estimated fair value of assets acquired was $54.7 million, and the estimated fair value of liabilities assumed was $9.1 million. The Purchase Price allocation as of the acquisition date is presented as follows (in thousands): July 28, 2020 Cash $ 42,990 Fair Value of CVRs 2,610 Total Purchase Price $ 45,600 Cash and cash equivalents $ 8,778 Accounts receivable 1,187 Inventory 4,767 Prepaid expenses and other current assets 1,218 Property and equipment 58 Right-of-use lease assets 2,302 Restricted cash 699 Identifiable intangible assets 15,520 Goodwill 20,123 Accounts payable (1,400 ) Accrued expenses (2,979 ) Lease liabilities, current portion (967 ) Lease liabilities, less current portion (1,420 ) Other noncurrent liabilities (2,286 ) Total Purchase Price $ 45,600 The estimated fair value of potential future cash payments pursuant to the CVRs was based on a Monte Carlo simulation and is classified as Level 3 in the ASC Topic 820-10, three-tier fair value hierarchy. CVRs are measured at fair value on a recurring basis. During the three and six months ended June 30, 2021, the Company recorded a $0.1 million gain and $0.4 million loss, respectively, in other (expense) income in the consolidated statements of operations resulting from the change in fair value of CVRs. The Company recorded a $3.3 million fair value step-up adjustment to Tetraphase’s inventory as of the acquisition date. Raw material components and active pharmaceutical ingredients were recorded based on estimated replacement cost. Finished drug product was valued at estimated selling cost, adjusted for costs of selling effort and a reasonable profit allowance for such selling effort from the viewpoint of a market participant. This fair value step-up adjustment is recorded as cost of product sales when the inventory is sold to customers, zero and $0.9 million of which was included in cost of product sales during the three and six months ended Identifiable intangible assets consist of certain technology and trade names acquired from Tetraphase, and include the value of the Harvard, Paratek and Everest Licenses (see Note 10). The acquired intangible assets have definite useful lives and are being amortized on a straight-line basis over an estimated useful life of 10 years. Goodwill represents the excess of the Purchase Price over the fair value of the net assets acquired as of the acquisition date. Goodwill represents the value of the stronger platform to increase patient access to the Company’s commercial products and the operational synergies of the combined Company. Goodwill has an indefinite useful life and is not amortized. The goodwill is only deductible for tax purposes if the Company makes a U.S. Internal Revenue Code Section 338 (“Section 338”) election. The Company did not make a Section 338 election.

Company-wide Realignment

Company-wide Realignment	6 Months Ended
	Jun. 30, 2021
Restructuring And Related Activities [Abstract]
Company-wide Realignments	12. Company-wide Realignments On May 28, 2020, the Board of Directors of the Company approved a restructuring plan (the “2020 Realignment”) to align its organization with the Company’s sole focus on the commercialization of its products. The 2020 Realignment reduced the Company’s headcount. For the year ended December 31, 2020, total expense was comprised of $4.1 million for one-time termination benefits to the affected employees, including severance and health care benefits, offset by a $0.4 million reversal of non-cash, share-based compensation expense related to forfeited, unvested equity awards. As of June 30, 2021, the Company had made substantially all of the payments related to the 2020 Realignment. In connection with the acquisition of Tetraphase, the Company incurred one-time charges related to a reduction in the combined Company’s headcount. For the year ended December 31, 2020, total expense was comprised of $3.1 million for one-time termination benefits to the affected employees, including severance and health care benefits. As of June 30, 2021, the Company had made substantially all of the payments related to this reduction in headcount.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	13. Income Taxes For the three and six months ended June 30, 2021, the Company recorded a provision for income taxes of zero and $18,000, respectively. For the three and six months ended June 30, 2020, the Company did not record a provision for income taxes. As of June 30, 2021 and December 31, 2020, the Company established a full valuation allowance against its federal and state deferred tax assets due to the uncertainty surrounding the realization of such assets. There were no unrecognized tax benefits as of June 30, 2021 and December 31, 2020. The Company does not anticipate there will be a significant change in unrecognized tax benefits within the next 12 months.

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation and Use of Estimates
Principles of Consolidation	The accompanying condensed consolidated financial statements include the accounts of La Jolla Pharmaceutical Company and its wholly owned subsidiaries. All inter-company transactions and balances have been eliminated in consolidation.
Use of Estimates	The preparation of the Company’s condensed consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in the Company’s condensed consolidated financial statements and the accompanying notes. Actual results may differ materially from these estimates. Certain amounts previously reported in the financial statements have been reclassified to conform to the current year presentation. Such reclassifications did not affect net loss, shareholders’ deficit or cash flows. The results of operations for the three and six months ended June 30, 2021 are not necessarily indicative of the results to be expected for the full year or any future interim periods. The accompanying condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited consolidated balance sheet as of December 31, 2020 contained in the Form 10-K.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist of cash. The Company maintains its cash in checking and savings accounts at federally insured financial institutions in excess of federally insured limits. During the six months ended June 30, 2021, 399 hospitals in the U.S. purchased GIAPREZA. During the six months ended June 30, 2021, 644 hospitals and other healthcare organizations in the U.S. purchased XERAVA. Hospitals and other healthcare organizations U.S. Net Product Sales Accounts Receivable Three Months Ended June 30, 2021 Six Months Ended June 30, 2021 As of June 30, 2021 Customer A 34 % 36 % 37 % Customer B 35 % 34 % 48 % Customer C 27 % 26 % 12 % Total 96 % 96 % 97 %
Business Combinations	Business Combinations The Company accounts for business combinations using the acquisition method pursuant to the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”)
Intangible Assets	Intangible Assets Intangible assets acquired in a business combination are initially recorded at fair value. Intangible assets with a definite useful life are amortized on a straight-line basis over the estimated useful life of the related assets. Intangible assets with an indefinite useful life are not amortized. The Company reviews its intangible assets for impairment at least annually or whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If such circumstances are determined to exist, an estimate of undiscounted future cash flows produced by the asset, including its eventual residual value, is compared to the carrying value to determine whether impairment exists. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Fair value is estimated through discounted cash flow models to project cash flows from the asset. The Company recognized no impairment charge for the six months ended June 30 , 2021 .
Goodwill	Goodwill Goodwill represents the excess of the Purchase Price over the fair value of the net assets acquired as of the acquisition date. Goodwill has an indefinite useful life and is not amortized. The Company reviews its goodwill for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of the Company may exceed its fair value. The Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of the Company is less than its carrying amount, including goodwill. If that is the case, the Company performs a quantitative impairment test, and, if the carrying amount of the Company exceeds its fair value, then the Company will recognize an impairment charge for the amount by which its carrying amount exceeds its fair value, not to exceed the carrying amount of the goodwill. The Company recognized no impairment charge for the six months ended June 30, 2021.
Revenue Recognition	Revenue Recognition Pursuant to FASB ASC Topic 606 Product Sales Revenue from product sales is recorded at the transaction price, net of estimates for variable consideration consisting of chargebacks, discounts, returns, Medicaid rebates and administrative fees. Variable consideration is estimated using the expected-value amount method, which is the sum of probability-weighted amounts in a range of possible consideration amounts. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results vary materially from the Company’s estimates, the Company will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted. These items include: • Chargebacks—Chargebacks are discounts the Company provides to distributors in the event that the sales prices to end users are below the distributors’ acquisition price. This may occur due to a direct contract with a health system, a group purchasing organization (“GPO”) agreement or a sale to a government facility. Chargebacks are estimated based on known chargeback rates and recorded as a reduction of revenue on delivery to the Company’s customers. • Discounts—The Company offers customers various forms of incentives and consideration, including prompt-pay and other discounts. The Company estimates discounts primarily based on contractual terms. These discounts are recorded as a reduction of revenue on delivery to the Company’s customers. • Returns—The Company offers customers a limited right of return, generally for damaged or expired product. The Company estimates returns based on an internal analysis, which includes actual experience. The estimates for returns are recorded as a reduction of revenue on delivery to the Company’s customers. • Medicaid Rebates—We participate in Medicaid rebate programs, which provide assistance to certain low-income patients based on each individual state’s guidelines regarding eligibility and services. Under the Medicaid rebate programs, we pay a rebate to each participating state, generally within three months after the quarter in which product was sold. The estimates for rebates are recorded as a reduction of revenue on delivery to the Company’s customers . • Administrative Fees—The Company pays administrative fees to GPOs for services and access to data. Additionally, the Company pays an Industrial Funding Fee as part of the U.S. General Services Administration’s Federal Supply Schedules program. These fees are based on contracted terms and are paid after the quarter in which the product was purchased by the applicable GPO or government agency. Administrative fees are recorded as a reduction of revenue on delivery to customers. The Company will continue to assess its estimates of variable consideration as it accumulates additional historical data and will adjust these estimates accordingly. License Revenue We enter into out-license agreements with counterparties to develop and/or commercialize our products in territories outside of the U.S. in exchange for: (i) nonrefundable, upfront license fees; (ii) development and regulatory milestone payments; and/or (iii) sales-based royalties and milestones. If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from nonrefundable, upfront fees allocated to the license when the license is transferred to the customer and the customer can benefit from the license. For licenses that are bundled with other performance obligations, management uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable, upfront fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of progress and related revenue recognition. At the inception of each arrangement that include milestone and other payments, other than sales-based milestone payments and nonrefundable, upfront license fees, we evaluate whether achieving each milestone payment or other payment is considered probable and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestone payments that are not within our control, such as approvals from regulators or where attainment of the specified event is dependent on the development activities of a third party, are not considered probable of being achieved until those approvals are received or the specified event occurs. For arrangements that include sales-based royalties and milestone payments, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of: (i) when the related sales occur; or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. We enter into commercial supply agreements with our out-licensees to supply our products in territories outside the U.S. in exchange for: (i) nonrefundable, upfront fees; and/or (ii) the reimbursement of manufacturing costs, plus a margin in certain cases. The Company is considered the principal in these arrangements for accounting purposes as it controls the promised goods before transferring these goods to the out-licensee. The Company recognizes revenue when out-licensees obtain control of the Company’s product, which typically occurs on delivery.
Recent Accounting Pronouncements	Recent Accounting Pronouncements The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position and results of operations.

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Schedule of Concentration Risk	The following table includes the percentage of U.S. net product sales and accounts receivable balances for the Company’s three major customers, each of which comprised 10% or more of its U.S. net product sales: U.S. Net Product Sales Accounts Receivable Three Months Ended June 30, 2021 Six Months Ended June 30, 2021 As of June 30, 2021 Customer A 34 % 36 % 37 % Customer B 35 % 34 % 48 % Customer C 27 % 26 % 12 % Total 96 % 96 % 97 %

Balance Sheet Details (Tables)

Balance Sheet Details (Tables)	6 Months Ended
	Jun. 30, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Schedule of Inventory	Inventory, net consisted of the following (in thousands): June 30, December 31, 2021 2020 Raw materials $ 802 $ 802 Work-in-process 3,636 3,213 Finished goods 1,043 1,998 Total inventory, net $ 5,481 $ 6,013
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consisted of the following (in thousands): June 30, December 31, 2021 2020 Refundable withholding tax $ 3,375 $ - Prepaid manufacturing costs 491 930 Prepaid clinical costs 265 820 Prepaid insurance 263 505 Other prepaid expenses and current assets 807 1,133 Total prepaid expenses and other current assets $ 5,201 $ 3,388
Property, Plant and Equipment	Property and equipment, net consisted of the following (in thousands): June 30, December 31, 2021 2020 Furniture and fixtures $ 313 $ 309 Computer hardware 310 310 Software 203 733 Total property and equipment, gross 826 1,352 Accumulated depreciation and amortization (663 ) (1,137 ) Total property and equipment, net $ 163 $ 215
Schedule of Intangible Assets, Net	Intangible assets, net consisted of the following (in thousands): Useful Life June 30, December 31, (years) 2021 2020 Technology 10 $ 14,000 $ 14,000 Trade name 10 1,520 1,520 Total intangible assets, gross 15,520 15,520 Accumulated amortization (1,423 ) (647 ) Total intangible assets, net $ 14,097 $ 14,873
Accrued Expenses	Accrued expenses consisted of the following (in thousands): June 30, December 31, 2021 2020 Accrued interest expense on deferred royalty obligation, current portion $ 4,227 $ 3,567 Deferred revenue 3,037 188 Accrued royalties and in-license fees 1,235 685 Accrued manufacturing costs 1,469 627 Accrued professional fees 942 660 Accrued other 1,265 767 Total accrued expenses $ 12,175 $ 6,494
Schedule of Other Noncurrent Liabilities	Other noncurrent liabilities consisted of the following (in thousands): June 30, December 31, 2021 2020 Paycheck Protection Program loan $ 2,313 $ 2,302 Fair value of contingent value rights (see Note 11) 2,180 1,810 Total other noncurrent liabilities $ 4,493 $ 4,112

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2021
Leases [Abstract]
Schedule of Future Minimum Lease Payments Excluding Operating Costs	Future minimum lease payments, excluding Lease Operating Costs, as of June 30, 2021 are as follows (in thousands): 2021 $ 108 2022 181 2023 166 Thereafter - Total future minimum lease payments 455 Less: discount 36 Total lease liabilities $ 419

Equity Incentive Plans (Tables)

Equity Incentive Plans (Tables)	6 Months Ended
	Jun. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Equity Award Activity	The activity related to equity awards, which are comprised of stock options, during the six months ended June 30, 2021 is summarized as follows: Equity Awards Weighted- average Exercise Price per Share Weighted- average Remaining Contractual Term ( 1) (years) Aggregate Intrinsic Value ( 2) (millions) Outstanding at December 31, 2020 4,121,666 $ 8.67 Granted 562,329 $ 4.96 Exercised (29,379 ) $ 5.23 Cancelled/forfeited (569,549 ) $ 9.21 Outstanding at June 30, 2021 4,085,067 $ 8.10 8.3 $ 0.2 Exercisable at June 30, 2021 1,107,878 $ 16.71 5.7 $ - (1) (2)
Share-based Compensation Expense	The classification of share-based compensation expense is summarized as follows (in thousands): Three Months Ended Six Months Ended June 30, June 30, 2021 2020 2021 2020 Selling, general and administrative $ 977 $ 626 $ 1,817 $ 1,470 Research and development 47 964 323 2,527 Total share-based compensation expense $ 1,024 $ 1,590 $ 2,140 $ 3,997

Acquisition of Tetraphase Pha_2

Acquisition of Tetraphase Pharmaceuticals, Inc (Tables)	6 Months Ended
	Jun. 30, 2021
Business Combinations [Abstract]
Summary of Purchase Price Allocation as of Acquisition Date	The Purchase Price allocation as of the acquisition date is presented as follows (in thousands): July 28, 2020 Cash $ 42,990 Fair Value of CVRs 2,610 Total Purchase Price $ 45,600 Cash and cash equivalents $ 8,778 Accounts receivable 1,187 Inventory 4,767 Prepaid expenses and other current assets 1,218 Property and equipment 58 Right-of-use lease assets 2,302 Restricted cash 699 Identifiable intangible assets 15,520 Goodwill 20,123 Accounts payable (1,400 ) Accrued expenses (2,979 ) Lease liabilities, current portion (967 ) Lease liabilities, less current portion (1,420 ) Other noncurrent liabilities (2,286 ) Total Purchase Price $ 45,600

Business - Additional Informati

Business - Additional Information (Details) - USD ($) $ in Thousands	Jan. 12, 2021	Jul. 28, 2020	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020
Business Acquisition [Line Items]
Cash and cash equivalents			$ 45,888	$ 21,221	$ 68,353
License Agreement
Business Acquisition [Line Items]
Proceeds from upfront cash payment	$ 22,500
Percentage of refundable tax withholding	15.00%
Commercial milestone payments	$ 109,500
Tetraphase Pharmaceuticals, Inc.
Business Acquisition [Line Items]
Upfront cash for acquisition		$ 42,990
Future cash payments		$ 16,000

Basis of Presentation and Sum_4

Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)	6 Months Ended
	Jun. 30, 2021USD ($)HospitalCustomer
Concentration Risk [Line Items]
Number of major customers | Customer	3
Impairment of intangible assets | $	$ 0
Goodwill impairment charges | $	$ 0
U.S.
Concentration Risk [Line Items]
Number of hospitals purchased GIAPREZA | Hospital	399
Number of hospitals and other healthcare organizations purchased XERAVA | Hospital	644

Basis of Presentation and Sum_5

Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details)	3 Months Ended	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2021
U.S. Net Product Sales
Concentration Risk [Line Items]
Concentration of credit risk	96.00%	96.00%
Accounts Receivable
Concentration Risk [Line Items]
Concentration of credit risk		97.00%
Customer A | U.S. Net Product Sales
Concentration Risk [Line Items]
Concentration of credit risk	34.00%	36.00%
Customer A | Accounts Receivable
Concentration Risk [Line Items]
Concentration of credit risk		37.00%
Customer B | U.S. Net Product Sales
Concentration Risk [Line Items]
Concentration of credit risk	35.00%	34.00%
Customer B | Accounts Receivable
Concentration Risk [Line Items]
Concentration of credit risk		48.00%
Customer C | U.S. Net Product Sales
Concentration Risk [Line Items]
Concentration of credit risk	27.00%	26.00%
Customer C | Accounts Receivable
Concentration Risk [Line Items]
Concentration of credit risk		12.00%

Earnings (Loss) per Share - Add

Earnings (Loss) per Share - Additional Information (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Earnings Per Share [Abstract]
Potentially dilutive common shares related to the outstanding preferred stock, stock options, restricted stock units and warrants (in shares)	4,100,000	4,100,000	10,200,000	10,200,000
Potential common shares that were included in the calculation of diluted earnings per share	6,700,000		6,700,000
Issuance of common stock up on conversion of preferred stock	6,700,000		6,700,000
Stock options	5,000		13,000

Balance Sheet Details - Additio

Balance Sheet Details - Additional Information (Details) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Apr. 22, 2020
Restricted Cash And Cash Equivalents Items [Line Items]
Restricted cash	$ 40,000	$ 40,000	$ 606,000
Inventory, net	5,481,000	5,481,000		$ 6,013,000
Inventory reserves	1,200,000	1,200,000		900,000
Amortization expense	400,000	776,000	$ 0
Promissory note					$ 2,300,000
Debt instrument, interest rate					1.00%
Tetraphase Pharmaceuticals, Inc. | Fair Value Step-Up Adjustment to Inventory
Restricted Cash And Cash Equivalents Items [Line Items]
Inventory, net	0	0		900,000
Credit Card
Restricted Cash And Cash Equivalents Items [Line Items]
Restricted cash	$ 40,000	$ 40,000		$ 40,000

Balance Sheet Details - Schedul

Balance Sheet Details - Schedule of Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Raw materials	$ 802	$ 802
Work-in-process	3,636	3,213
Finished goods	1,043	1,998
Total inventory, net	$ 5,481	$ 6,013

Balance Sheet Details - Sched_2

Balance Sheet Details - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Prepaid Expense And Other Assets [Abstract]
Refundable withholding tax	$ 3,375
Prepaid manufacturing costs	491	$ 930
Prepaid clinical costs	265	820
Prepaid insurance	263	505
Other prepaid expenses and current assets	807	1,133
Total prepaid expenses and other current assets	$ 5,201	$ 3,388

Balance Sheet Details - Propert

Balance Sheet Details - Property Plant and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Property Plant And Equipment [Line Items]
Total property and equipment, gross	$ 826	$ 1,352
Accumulated depreciation and amortization	(663)	(1,137)
Total property and equipment, net	163	215
Furniture and Fixtures [Member]
Property Plant And Equipment [Line Items]
Total property and equipment, gross	313	309
Computer Equipment [Member]
Property Plant And Equipment [Line Items]
Total property and equipment, gross	310	310
Software and Software Development Costs [Member]
Property Plant And Equipment [Line Items]
Total property and equipment, gross	$ 203	$ 733

Balance Sheet Details - Sched_3

Balance Sheet Details - Schedule of Intangible Assets, Net (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Finite Lived Intangible Assets [Line Items]
Total intangible assets, gross	$ 15,520	$ 15,520
Accumulated amortization	(1,423)	(647)
Total intangible assets, net	14,097	14,873
Technology
Finite Lived Intangible Assets [Line Items]
Total intangible assets, gross	$ 14,000	$ 14,000
Useful Life (years)	10 years	10 years
Trade Name
Finite Lived Intangible Assets [Line Items]
Total intangible assets, gross	$ 1,520	$ 1,520
Useful Life (years)	10 years	10 years

Balance Sheet Details - Summary

Balance Sheet Details - Summary of Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Accrued interest expense on deferred royalty obligation, current portion	$ 4,227	$ 3,567
Deferred revenue	3,037	188
Accrued royalties and in-license fees	1,235	685
Accrued manufacturing costs	1,469	627
Accrued professional fees	942	660
Accrued other	1,265	767
Total accrued expenses	$ 12,175	$ 6,494

Balance Sheet Details - Sched_4

Balance Sheet Details - Schedule of Other Noncurrent Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Other Liabilities Noncurrent [Abstract]
Paycheck Protection Program loan	$ 2,313	$ 2,302
Fair value of contingent value rights (see Note 11)	2,180	1,810
Total other noncurrent liabilities	$ 4,493	$ 4,112

Deferred Royalty Obligation - A

Deferred Royalty Obligation - Additional Information (Details) - USD ($) $ in Thousands	May 10, 2018	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Debt Instrument [Line Items]
Deferred royalty obligation, net		$ 124,470		$ 124,470		$ 124,437
Interest expense		2,700	$ 2,500	5,300	$ 4,900
Royalty obligation payable		900		900		900
HealthCare Royalty Partners
Debt Instrument [Line Items]
Proceeds from royalty agreement	$ 125,000
Required payment for breach of agreement, payment two	225,000
Required payment for breach of agreement, payment one	125,000
HealthCare Royalty Partners | Royalty Financing Agreement | Loans Payable
Debt Instrument [Line Items]
Deferred royalty obligation, net	125,000	124,500		124,500		124,400
Debt issuance costs	$ 700
Unamortized debt discount		500		500		600
Accrued interest expense		26,400		26,400		22,700
Royalty payments		700		1,600
HealthCare Royalty Partners | Royalty Financing Agreement | Loans Payable | Other Noncurrent Liabilities
Debt Instrument [Line Items]
Accrued interest expense		$ 22,100		$ 22,100		$ 19,100
HealthCare Royalty Partners | Period One
Debt Instrument [Line Items]
Maximum potential royalty payout	10.00%
HealthCare Royalty Partners | Period Two
Debt Instrument [Line Items]
Increase in maximum potential payout percent	4.00%
HealthCare Royalty Partners | Payout Period
Debt Instrument [Line Items]
Increase in maximum potential payout percent	4.00%

Commitments and Contingencies -

Commitments and Contingencies - Future Minimum Lease Payments Excluding Operating Costs (Details) $ in Thousands	Jun. 30, 2021USD ($)
Leases [Abstract]
2021	$ 108
2022	181
2023	166
Total future minimum lease payments	455
Less: discount	36
Total lease liabilities	$ 419

Commitments and Contingencies_2

Commitments and Contingencies - Additional Information (Details) - USD ($)	1 Months Ended		3 Months Ended		6 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Lessee Lease Description [Line Items]
Lease expense			$ 100,000	$ 700,000	$ 200,000	$ 1,400,000
Operating lease, cash payments			$ 51,000	$ 1,000,000	$ 100,000	$ 1,900,000
Operating lease weighted-average remaining lease term			2 years 3 months 18 days		2 years 3 months 18 days
Operating lease weighted-average discount rate			3.50%		3.50%
Waltham Sublease
Lessee Lease Description [Line Items]
Expiration date	Nov. 30, 2023
Sublease rent per month	$ 15,000
San Diego Sublease
Lessee Lease Description [Line Items]
Sublease rent per month		$ 12,000
Sublease term		7 years
Sublease cancellable written notice period		30 days
Payments of sublease			$ 28,000		$ 67,000

Shareholders' Equity - Addition

Shareholders' Equity - Additional Information (Details) - Series C-1 Convertible Preferred Stock - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Class Of Stock [Line Items]
Preferred stock, shares issued (in shares)	3,906	3,906
Convertible Preferred Stock, Shares Reserved for Future Issuance	6,735,378	6,735,378
Preferred stock, liquidation preference	$ 3,906	$ 3,906

Equity Incentive Plans - Narrat

Equity Incentive Plans - Narrative (Details) - USD ($)	6 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unamortized share-based compensation expense	$ 8,900,000
Recognized weighted average period	3 years
2013 Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares reserved for issuance	9,600,000
Shares available for grant (in shares)	5,514,933	5,478,334
2018 Employee Stock Purchase Plan [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares reserved for issuance	750,000
Shares available for grant (in shares)	405,564	455,768
Unrecognized share-based compensation expense	$ 0

Equity Incentive Plans - Stock

Equity Incentive Plans - Stock Option Activity (Details) $ / shares in Units, $ in Millions	6 Months Ended
	Jun. 30, 2021USD ($)$ / sharesshares
Shares Underlying Stock Options
Outstanding beginning balance, Shares underlying stock options and restricted stock awards (in shares) | shares	4,121,666
Granted, Shares underlying stock options and restricted stock awards (in shares) | shares	562,329
Exercised, Shares underlying stock options and restricted stock awards (in shares) | shares	(29,379)
Cancelled/Forfeited, Shares underlying stock options and restricted stock awards (in shares) | shares	(569,549)
Outstanding ending balance, Shares underlying stock options and restricted stock awards (in shares) | shares	4,085,067
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Shares | shares	1,107,878
Weighted- Average Exercise Price per Share
Outstanding beginning balance, Weighted - average exercise price (usd per share) | $ / shares	$ 8.67
Granted, Weighted - average exercise price (usd per share) | $ / shares	4.96
Exercised, Weighted - average exercise price (usd per share) | $ / shares	5.23
Cancelled/forfeited, Weighted - average exercise price (usd per share) | $ / shares	9.21
Outstanding ending balance, Weighted - average exercise price (usd per share) | $ / shares	8.10
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | $ / shares	$ 16.71
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	8 years 3 months 18 days	[1]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	5 years 8 months 12 days	[1]
Outstanding, Aggregate Intrinsic Value | $	$ 0.2	[2]
[1]	Represents the weighted-average remaining contractual term of stock options.
[2]	Aggregate intrinsic value represents the product of the number of equity awards outstanding or equity awards exercisable multiplied by the difference between the Company’s closing stock price per share on the last trading day of the period, which was $4.28 as of June 30, 2021, and the exercise price.

Equity Incentive Plans - Stoc_2

Equity Incentive Plans - Stock Option Activity (Parenthetical) (Details)	6 Months Ended
	Jun. 30, 2021$ / shares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Change of equity awards outstanding or equity awards, exercise price	$ 4.28

Equity Incentive Plans - Share-

Equity Incentive Plans - Share-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 1,024	$ 1,590	$ 2,140	$ 3,997
Selling, General and Administrative Expenses [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	977	626	1,817	1,470
Research and development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 47	$ 964	$ 323	$ 2,527

Other Income-Related Party - Ad

Other Income-Related Party - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Related Party Transactions [Abstract]
Other income—related party	$ 2,532,000	$ 0	$ 2,532,000	$ 4,085,000

License Agreements - Additional

License Agreements - Additional Information (Details) - USD ($)	Jul. 13, 2021	Jan. 12, 2021	May 31, 2021	Mar. 31, 2021	Mar. 31, 2019	Jun. 30, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020
License Revenue
Research And Development Arrangement Contract To Perform For Others [Line Items]
Revenue						$ 5,000,000			$ 30,500,000
George Washington
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payment								$ 500,000
Percentage of royalty on net sales									6.00%
Percentage of payments received from sublicensee									15.00%
Royalty payments						400,000	$ 500,000		$ 3,200,000	$ 900,000
Harvard
Research And Development Arrangement Contract To Perform For Others [Line Items]
Percentage of royalty on net sales									5.00%
Percentage of payments received from sublicensee									20.00%
Clinical development and regulatory milestones amount payable									$ 15,100,000
Percentage of minimum royalty rate									4.50%
Percentage of maximum royalty based on achievement of annual net product sales thresholds									7.50%
Royalties payments						1,500,000			$ 1,600,000
Payments related to clinical development and regulatory milestones						0			0
Paratek
Research And Development Arrangement Contract To Perform For Others [Line Items]
Percentage of royalty on net sales					2.25%
Royalties payments						40,000			$ 100,000
Claim expiration									2023-10
PAION AG
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payment		$ 109,500,000
Upfront cash payment		$ 22,500,000
Percentage of refundable tax withholding		15.00%
PAION AG | Subsequent Event
Research And Development Arrangement Contract To Perform For Others [Line Items]
Supply agreement term	3 years
Everest Medicines Limited
Research And Development Arrangement Contract To Perform For Others [Line Items]
Additional regulatory milestone payments receivable						8,000,000			$ 8,000,000
Sales milestone payments receivable						20,000,000			$ 20,000,000
Royalties payable description									Royalties are payable with respect to each jurisdiction in the Everest Territory until the latest to occur of: (1) the last-to-expire of specified patent rights in such jurisdiction in the Everest Territory; (2) expiration of marketing or regulatory exclusivity in such jurisdiction in the Everest Territory; or (3) 10 years after the first commercial sale of a product in such jurisdiction in the Everest Territory.
Royalties payable period after first commercial sale of product									10 years
Milestone payments received				$ 3,000,000
Everest Medicines Limited | Commercial Supply Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Proceeds from upfront payments			$ 6,800,000
Proceeds from upfront technology transfer payment			4,000,000
Proceeds from partial prepayment for XERAVA			2,800,000
Additional technology transfer payment receivable by January 30, 2022			$ 1,000,000
Percentage of reimbursed for direct and certain indirect manufacturing costs through December 31, 2023			110.00%
Deferred revenue						2,800,000			$ 2,800,000
Everest Medicines Limited | Commercial Supply Agreement | License Revenue
Research And Development Arrangement Contract To Perform For Others [Line Items]
Revenue						$ 5,000,000			$ 5,000,000

Acquisition of Tetraphase Pha_3

Acquisition of Tetraphase Pharmaceuticals, Inc. Additional Information (Details) - USD ($)	Jul. 28, 2020	Jun. 30, 2021	Jun. 30, 2021
Business Acquisition [Line Items]
Inventory fair value step up adjustment			$ 850,000
Tetraphase Pharmaceuticals, Inc.
Business Acquisition [Line Items]
Business acquisition, date of acquisition agreement	Jun. 24, 2020
Upfront cash for acquisition	$ 42,990,000
Future cash payments	16,000,000
Additional aggregate payments	16,000,000
Business acquisition, description			The holders of the CVRs are entitled to receive potential future cash payments of up to $16 million in the aggregate upon the achievement of certain net sales of XERAVA in the U.S. as follows: (i) $2.5 million if 2021 XERAVA U.S. net sales are at least $20 million; (ii) $4.5 million if XERAVA U.S. net sales are at least $35 million during any calendar year ending on or prior to December 31, 2024; and (iii) $9 million if XERAVA U.S. net sales are at least $55 million during any calendar year ending on or prior to December 31, 2024.
Estimated fair value of assets acquired	54,700,000
Estimated fair value of liabilities assumed	9,100,000
Gail (loss) recorded in other (expense) income resulting from the change in fair value of CVRs		$ 100,000	$ (400,000)
Inventory fair value step up adjustment	$ 3,300,000
Weighted-average Years	10 years
Tetraphase Pharmaceuticals, Inc. | Cost of Product Sales
Business Acquisition [Line Items]
Inventory fair value step up adjustment		$ 0	$ 900,000
Agreement 1 | Tetraphase Pharmaceuticals, Inc.
Business Acquisition [Line Items]
Proceeds from businesses and interest in affiliates	$ 2,500,000
Net sales from related parties	20,000,000
Agreement 2 | Tetraphase Pharmaceuticals, Inc.
Business Acquisition [Line Items]
Proceeds from businesses and interest in affiliates	4,500,000
Net sales from related parties	35,000,000
Agreement 3 | Tetraphase Pharmaceuticals, Inc.
Business Acquisition [Line Items]
Proceeds from businesses and interest in affiliates	9,000,000
Net sales from related parties	$ 55,000,000

Acquisition of Tetraphase Pha_4

Acquisition of Tetraphase Pharmaceuticals, Inc - Summary of Purchase Price Allocation as of Acquisition Date (Details) - USD ($) $ in Thousands	Jul. 28, 2020	Jun. 30, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Goodwill		$ 20,123	$ 20,123
Tetraphase Pharmaceuticals, Inc.
Business Acquisition [Line Items]
Cash	$ 42,990
Fair Value of CVRs	2,610
Total Purchase Price	45,600
Cash and cash equivalents	8,778
Accounts receivable	1,187
Inventory	4,767
Prepaid expenses and other current assets	1,218
Property and equipment	58
Right-of-use lease assets	2,302
Restricted cash	699
Identifiable intangible assets	15,520
Goodwill	20,123
Accounts payable	(1,400)
Accrued expenses	(2,979)
Lease liabilities, current portion	(967)
Lease liabilities, less current portion	(1,420)
Other noncurrent liabilities	$ (2,286)

Company-wide Realignments - Add

Company-wide Realignments - Additional Information (Details) $ in Millions	12 Months Ended
	Dec. 31, 2020USD ($)
Restructuring Cost And Reserve [Line Items]
Reversal of non-cash-stock-based compensation expense	$ 0.4
Restructuring costs	4.1
Tetraphase Pharmaceuticals, Inc.
Restructuring Cost And Reserve [Line Items]
Restructuring costs	$ 3.1

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Provision for income tax	$ 0	$ 0	$ 18,000	$ 0
Unrecognized tax benefits	$ 0		$ 0		$ 0